Key result
Novel ClC-K channel inhibitors show micromolar potency, offering potential new targets for hypertension.
Why the study?
ClC-K chloride channels play a key role in renal physiology and pathology, making them important targets for drug discovery in tubulopathies and cardiovascular diseases.
Do small molecules targeting kidney ClC-K chloride channels improve physiological parameters in models of rare tubulopathies and cardiovascular diseases?
Do small molecules targeting kidney ClC-K chloride channels improve physiological parameters in models of rare tubulopathies and cardiovascular diseases?
The identification of specific small molecule modulators of ClC-K channels provides a targeted pharmacological approach for treating Bartter syndrome and managing cardiovascular conditions such as hypertension and heart failure.
ClC-K inhibitors remain investigational; leaves open selective agent development and trials before hypertension use.
Given the key role played by ClC-K chloride channels in kidney and inner ear physiology and pathology, they can be considered important targets for drug discovery. Indeed, ClC-Ka and ClC-Kb inhibition would interfere with the urine countercurrent concentration mechanism in Henle's loop, which is responsible for the reabsorption of water and electrolytes from the collecting duct, producing a diuretic and antihypertensive effect. On the other hand, ClC-K/barttin channel dysfunctions in Bartter Syndrome with or without deafness will require the pharmacological recovery of channel expression and/or activity. In these cases, a channel activator or chaperone would be appealing. Starting from a brief description of the physio-pathological role of ClC-K channels in renal function, this review aims to provide an overview of the recent progress in the discovery of ClC-K channel modulators.
No takes yet. Share an insight, caveat, or question.
Coppola et al. (2023) conducted a review in Bartter Syndrome, hypertension, heart failure. ClC-K channel modulators was evaluated. Small molecule modulators, including benzofuran derivatives and valsartan, were identified as ClC-K channel inhibitors with micromolar IC50 values, offering potential applications for hypertension.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: